Efficacy and Safety of Inhaler Steroids in COPD Patients: Systematic Review and Meta-analysis of Randomized Placebo-controlled Trials

Overview

Journal Caspian J Intern Med

Specialty General Medicine

Date 2014 Sep 10

PMID 25202439

Citations 2

Authors

Reza Karbasi-Afshar

Jafar Aslani

Mostafa Ghanei

Affiliations

Soon will be listed here.

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a major health dilemma and cause of morbidity and mortality in either industrialized or developing countries and inhaled corticosteroids are widely used worldwide in these patients. In this systematic review, we aimed to analyze the effectiveness of these gents compared to placebo.

Methods: Pubmed and Google Scholar literature search has been done to find randomized placebo-controlled trials investigating effectiveness of inhaled steroids in COPD patients. Finally, the data from 18 trials had been retrieved and included into a database, and analyzed using Stata ® v.9.0.

Results: Data of 12, 297 COPD subjects were analyzed. Analysis of survival of patients in the two groups showed no significant difference between those taking inhaled corticosteroids or placebo (relative risk (RR): 1.071, 95% confidence interval (CI): 0.938-1.224, P=0.309). Patients taking inhaled steroids were significantly less likely to develop an exacerbation episode (RR: 0.697, 95%CI: 0.596-0.816, p<0.001) or to have less withdrawal rate than placebo (RR: 0.882, 95%CI: 0.811-0.960; P=0.004).

Conclusion: Because steroid inhalers represent no survival effects in COPD patients, and due to their life threatening side effects (pneumonia, candidemia, etc.), we propose to replace steroid inhalers to cheaper agents which provide patients with comparable advantages (e.g. few exacerbations) and fewer side effects. Pulmonary rehabilitations as well as anti-inflammatory drugs are recommended to be more attended in COPD patients.

Citing Articles

Frequent Outpatient Visits Prevent Exacerbation of Chronic Obstructive Pulmonary Disease.

Park H, Byun M, Kim T, Rhee C, Kim K, Kim B Sci Rep. 2020; 10(1):6049.

PMID: 32269274 PMC: 7142121. DOI: 10.1038/s41598-020-63064-x.

The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.

Parumasivam T, Leung S, Tang P, Mauro C, Britton W, Chan H AAPS J. 2016; 19(1):191-202.

PMID: 27679516 DOI: 10.1208/s12248-016-9988-9.

References

Yang I, Fong K, Sim E, Black P, Lasserson T . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007; (2):CD002991. DOI: 10.1002/14651858.CD002991.pub2. View

Bryant J, McDonald V, Boyes A, Sanson-Fisher R, Paul C, Melville J . Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res. 2013; 14:109. PMC: 4015036. DOI: 10.1186/1465-9921-14-109. View

Doherty D, Tashkin D, Kerwin E, Knorr B, Shekar T, Banerjee S . Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7:57-71. PMC: 3276257. DOI: 10.2147/COPD.S27320. View

Xu W, Collet J, Shapiro S, Lin Y, Yang T, Wang C . Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J. 2009; 35(5):1022-30. DOI: 10.1183/09031936.00079409. View

Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K . Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999; 353(9167):1819-23. DOI: 10.1016/s0140-6736(98)10019-3. View

Rabe K, Hiemstra P . Theophylline for chronic obstructive pulmonary disease?....Time to move on. Am J Respir Crit Care Med. 2010; 182(7):868-9. DOI: 10.1164/rccm.201008-1271ED. View

Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A . Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361(9356):449-56. DOI: 10.1016/S0140-6736(03)12459-2. View

Bourbeau J, Rouleau M, Boucher S . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax. 1998; 53(6):477-82. PMC: 1745246. DOI: 10.1136/thx.53.6.477. View

Pauwels R, Lofdahl C, Laitinen L, Schouten J, Postma D, Pride N . Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999; 340(25):1948-53. DOI: 10.1056/NEJM199906243402503. View

10.

van Grunsven P, Schermer T, Akkermans R, Albers M, van den Boom G, Van Schayck O . Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respir Med. 2003; 97(12):1303-12. DOI: 10.1016/j.rmed.2003.08.001. View

11.

Renkema T, Schouten J, Koeter G, Postma D . Effects of long-term treatment with corticosteroids in COPD. Chest. 1996; 109(5):1156-62. DOI: 10.1378/chest.109.5.1156. View

12.

Tashkin D, Doherty D, Kerwin E, Matiz-Bueno C, Knorr B, Shekar T . Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis. 2012; 7:73-86. PMC: 3276258. DOI: 10.2147/COPD.S29444. View

13.

Mahler D, Wire P, Horstman D, Chang C, Yates J, Fischer T . Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166(8):1084-91. DOI: 10.1164/rccm.2112055. View

14.

Paggiaro P, Dahle R, BAKRAN I, Frith L, Hollingworth K, Efthimiou J . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998; 351(9105):773-80. DOI: 10.1016/s0140-6736(97)03471-5. View

15.

Albers M, Schermer T, van den Boom G, Akkermans R, van Schayck C, van Herwaarden C . Efficacy of inhaled steroids in undiagnosed subjects at high risk for COPD: results of the detection, intervention, and monitoring of COPD and asthma program. Chest. 2004; 126(6):1815-24. DOI: 10.1378/chest.126.6.1815. View

16.

Leung R, Alison J, McKeough Z, Peters M . A study design to investigate the effect of short-form Sun-style Tai Chi in improving functional exercise capacity, physical performance, balance and health related quality of life in people with Chronic Obstructive Pulmonary Disease (COPD). Contemp Clin Trials. 2010; 32(2):267-72. DOI: 10.1016/j.cct.2010.11.006. View

17.

Maltais F, Ostinelli J, Bourbeau J, Tonnel A, Jacquemet N, Haddon J . Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002; 165(5):698-703. DOI: 10.1164/ajrccm.165.5.2109093. View

18.

Drummond M, Dasenbrook E, Pitz M, Murphy D, Fan E . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300(20):2407-16. PMC: 4804462. DOI: 10.1001/jama.2008.717. View

19.

Hanania N, Darken P, Horstman D, Reisner C, Lee B, Davis S . The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003; 124(3):834-43. DOI: 10.1378/chest.124.3.834. View

20.

Gartlehner G, Hansen R, Carson S, Lohr K . Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med. 2006; 4(3):253-62. PMC: 1479432. DOI: 10.1370/afm.517. View